Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Avanir Pharmaceuticals Inc Issues FY 2013 Revenue Guidance In Line With Analysts' Estimates


Tuesday, 29 Oct 2013 08:30am EDT 

Avanir Pharmaceuticals Inc announced that based on preliminary financial information for the fiscal 2013, Avanir estimates total gross revenues of approximately $95.9 million (Non-GAAP); total net revenues in the range of approximately $75.3 million to $76.3 million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $75.6 million for fiscal 2013. 

Company Quote

3.46
0.04 +1.17%
17 Apr 2014